Opportunity Information: Apply for PA 19 043
The NIH funding opportunity "Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed)" (PA 19-043) is an SBIR-focused grant program designed to help small businesses create practical, broadly applicable tools and methods that connect human genetic variation to real biological function and, ultimately, to human health and disease. The central problem it targets is a common gap in modern genetics: large studies can often find statistical links between DNA variants and diseases or traits, but those links do not automatically reveal which exact variants are truly causal, what they do inside cells, or why they change disease risk. In parallel, clinical sequencing has produced huge numbers of identified variants in both healthy and sick individuals, yet many of these are labeled "variants of uncertain significance" (VUS) because their impact is unclear, which makes it difficult for clinicians to act on the information. This program is meant to move beyond association and uncertainty by supporting technologies that can test, interpret, and translate variant effects in a way that can be used in research and, potentially, clinical decision-making.
The goal of the announcement is explicitly developmental and commercialization-oriented. It supports the creation of novel and generalizable approaches, meaning NIH is looking for methods that are not limited to one gene, one disease, or one narrow experimental context, but can be reused across many variants, genomic regions, or conditions. The emphasis on "commercialized approaches" signals that the end product should be something a small business can realistically turn into a product, platform, service, assay, software pipeline, or other deliverable that the broader community can adopt. The funding mechanism is the SBIR R43/R44 pathway, which typically maps to a staged development process: Phase I (R43) supports early feasibility and proof-of-concept work, and Phase II (R44) supports more advanced R&D and refinement toward a market-ready solution. While the opportunity description does not list an award ceiling or expected number of awards in the provided text, it is clearly positioned as a discretionary NIH grant under CFDA 93.172 in the health category.
Scientifically, the program is focused on turning genetic findings into functional understanding. That can include, for example, approaches that identify which variant within a linked region is actually driving an effect, methods that measure how variants alter gene regulation, splicing, protein function, cellular pathways, or phenotypes, and strategies that help determine whether a variant is likely pathogenic, benign, or context-dependent. Because the problem of VUS is explicitly highlighted, solutions that improve variant interpretation for clinical sequencing are directly within scope, provided they remain consistent with the "clinical trial not allowed" limitation. In practical terms, NIH is signaling interest in tools that can generate evidence strong enough to reduce uncertainty around variants, improve classification, and make genomic information more actionable.
The "Clinical Trial Not Allowed" label means applicants should not propose clinical trials as part of the project. The work can still be clinically relevant, and it can be aimed at clinical utility, but it should not involve prospective assignment of human participants to interventions to evaluate health outcomes in a trial framework. Typical acceptable work in this kind of notice often includes laboratory validation, computational model development, retrospective analyses of existing data sets, development of assays, and other non-trial study designs, as long as they follow NIH rules for human subjects research when applicable.
Eligibility is restricted to small businesses, consistent with the SBIR program. The notice also makes clear that non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible to apply either. However, foreign components, as NIH defines them in its Grants Policy Statement, may be allowed in some cases, which generally means a U.S. applicant might be able to include certain discrete foreign activities if they are well-justified and meet NIH requirements, but the applicant organization itself must be domestic and eligible.
Administratively, the opportunity was created on 2018-10-31 and lists an original closing date of 2021-09-05 in the source data provided. It is described as part of a broader set of related NIH announcements that also include companion R21 and R01 opportunities, suggesting NIH is funding this scientific theme across multiple mechanisms, with this specific one tailored to small businesses pursuing product-oriented innovation.
Overall, this announcement is aimed at accelerating the translation of genetic discoveries into functional evidence and usable interpretation frameworks, with an emphasis on scalable, broadly deployable solutions that can move toward commercialization. The intended impact is to help the field progress from "this variant is associated with disease" to "this variant changes this biological function in this way, which affects disease risk or protection, and we can measure or predict that reliably enough to inform research and potentially clinical practice."Apply for PA 19 043
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
- This funding opportunity was created on 2018-10-31.
- Applicants must submit their applications by 2021-09-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH SBIR Funding Opportunity PA 19-043 (R43/R44) - Novel Approaches for Relating Genetic Variation to Function and Disease (Clinical Trial Not Allowed)
What is this funding opportunity?
This is an NIH Small Business Innovation Research (SBIR) funding opportunity titled "Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed)" (PA 19-043). It supports small businesses developing practical tools and methods that connect human genetic variation to biological function and, ultimately, to human health and disease.
What problem is NIH trying to solve with this program?
The program targets a common gap in modern genetics: large genetic studies can identify statistical associations between DNA variants and diseases or traits, but those associations often do not reveal which specific variants are causal, what they do in cells, or why they change disease risk. It also addresses the large number of variants found through clinical sequencing that are labeled variants of uncertain significance (VUS) because their effects are unclear.
What is the main goal of PA 19-043?
The main goal is to move beyond association and uncertainty by supporting technologies that can test, interpret, and translate variant effects into evidence that is usable in research and potentially in clinical decision-making, while staying within the "clinical trial not allowed" limitation.
Who is eligible to apply?
Eligibility is restricted to small businesses under the SBIR program. Non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply.
Are any foreign activities allowed?
Foreign components may be allowed in some cases, as defined by NIH policy, meaning a U.S. applicant might include certain discrete foreign activities if they are well-justified and meet NIH requirements. However, the applicant organization itself must be domestic and SBIR-eligible.
What does R43/R44 mean in this announcement?
R43/R44 refers to the SBIR phased award structure. Phase I (R43) generally supports early feasibility and proof-of-concept work. Phase II (R44) generally supports more advanced research and development and refinement toward a market-ready solution.
Is this opportunity focused on commercialization?
Yes. The announcement is explicitly developmental and commercialization-oriented. NIH is looking for approaches that a small business can realistically turn into a product, platform, service, assay, software pipeline, or other deliverable that can be adopted by the broader community.
What kinds of solutions are in scope?
Solutions are focused on turning genetic findings into functional understanding. Examples described in the opportunity include approaches that identify causal variants within linked regions, measure how variants alter gene regulation, splicing, protein function, cellular pathways, or phenotypes, and help determine whether variants are likely pathogenic, benign, or context-dependent.
Does the program specifically address variants of uncertain significance (VUS)?
Yes. The opportunity highlights the challenge of VUS and supports solutions that can reduce uncertainty around variants, improve classification, and make sequencing results more actionable, as long as the work remains consistent with the "clinical trial not allowed" limitation.
What does "Novel and generalizable approaches" mean here?
It means NIH is looking for methods that are not limited to a single gene, a single disease, or a narrow experimental context. The approach should be broadly applicable and reusable across many variants, genomic regions, or conditions.
Are clinical trials allowed under this opportunity?
No. The announcement is labeled "Clinical Trial Not Allowed," meaning applicants should not propose clinical trials as part of the project.
Can projects still be clinically relevant if clinical trials are not allowed?
Yes. The work can be clinically relevant and aimed at clinical utility, but it should not involve prospective assignment of human participants to interventions to evaluate health outcomes in a clinical trial framework.
What types of work are generally consistent with "Clinical Trial Not Allowed" based on the description?
The description indicates that typical acceptable work can include laboratory validation, computational model development, retrospective analyses of existing data sets, development of assays, development of software or pipelines, and other non-trial study designs, while following NIH rules for human subjects research when applicable.
What is the intended end result NIH wants to see?
The intended impact is to accelerate progress from "this variant is associated with disease" to "this variant changes biological function in a specific way that affects disease risk or protection, and we can measure or predict that reliably enough to inform research and potentially clinical practice."
Is the program limited to one disease area?
Based on the description, the program emphasizes broadly deployable solutions rather than approaches tied to one gene or one disease, indicating it is intended to be applicable across many conditions.
Does the opportunity mention a specific CFDA number or category?
Yes. It is described as an NIH grant under CFDA 93.172 in the health category.
Does the provided information list an award ceiling or number of awards?
No. The provided text does not list an award ceiling or the expected number of awards.
When was this opportunity created, and what closing date is shown in the provided information?
The opportunity was created on 2018-10-31 and the source data provided lists an original closing date of 2021-09-05.
Are there related NIH opportunities connected to this topic?
Yes. The description notes that this announcement is part of a broader set of related NIH announcements, including companion R21 and R01 opportunities, with this specific one tailored to small businesses pursuing product-oriented innovation.
What kinds of deliverables does NIH appear to expect from small businesses?
NIH signals interest in deliverables that others can adopt, such as products, platforms, services, assays, software pipelines, or other tools and methods that generate interpretable evidence about variant function and disease relevance.
Browse more opportunities from the same category: Health
Next opportunity: Humanities Initiatives at Hispanic-Serving Institutions
Previous opportunity: Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 19 043
Applicants also applied for:
Applicants who have applied for this opportunity (PA 19 043) also looked into and applied for these:
| Funding Opportunity |
|---|
| Advancing Research in Augmentative and Alternative Communication (AAC) (R21 Clinical Trial Optional) Apply for PA 19 046 Funding Number: PA 19 046 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Advancing Research in Augmentative and Alternative Communication (AAC) (R01 Clinical Trial Optional) Apply for PA 19 047 Funding Number: PA 19 047 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed) Apply for PAR 19 048 Funding Number: PAR 19 048 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Research Directions that Advance the NHLBI Strategic Vision Normal Biology (R21 - Clinical Trial Not Allowed) Apply for PA 19 049 Funding Number: PA 19 049 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Sustainable Access for Expanded Voluntary Medical Male circumcision (VMMC) Services (SAFE) Apply for SOURCES SOUGHT NOTICE 2018 Funding Number: SOURCES SOUGHT NOTICE 2018 Agency: Tanzania USAID-Dar es Salaam Category: Health Funding Amount: Case Dependent |
| Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed) Apply for RFA AG 20 004 Funding Number: RFA AG 20 004 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Investigator Initiated Research in Computational Genomics and Data Science (R43/R44 Clinical Trial Not Allowed) Apply for PAR 19 061 Funding Number: PAR 19 061 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Processing and Presentation of Non-Conventional MHC Ligands (R01 Clinical Trial Not Allowed) Apply for PA 19 067 Funding Number: PA 19 067 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Single-Cell Multi-Omics of HIV Persistence (R01 Clinical Trial Not Allowed) Apply for RFA AI 18 053 Funding Number: RFA AI 18 053 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed) Apply for PA 19 066 Funding Number: PA 19 066 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed) Apply for PA 19 068 Funding Number: PA 19 068 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed) Apply for RFA DE 19 008 Funding Number: RFA DE 19 008 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed) Apply for RFA DE 19 009 Funding Number: RFA DE 19 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Medications Development for the Treatment of Alcohol Use Disorder (U01 Clinical Trial Optional) Apply for RFA AA 19 005 Funding Number: RFA AA 19 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) Apply for PAR 19 070 Funding Number: PAR 19 070 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed) Apply for PAR 19 071 Funding Number: PAR 19 071 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 18 057 Funding Number: RFA AI 18 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R21 Clinical Trial Optional) Apply for RFA MH 19 411 Funding Number: RFA MH 19 411 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R34 Clinical Trial Required) Apply for RFA MH 19 410 Funding Number: RFA MH 19 410 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R01 Clinical Trial Optional) Apply for RFA MH 19 412 Funding Number: RFA MH 19 412 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 19 043", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.